Leu-enkephalin vs Met-enkephalin

How they're alike

Leu-enkephalin (YGGFL) and Met-enkephalin (YGGFM) are the two founding endogenous opioid pentapeptides and were historically identified together as the pentapeptide ligands of the opioid receptor system (Goumon and colleagues 1996). Both are liberated from the same precursor protein, proenkephalin-A (PENK), through cleavage at paired-basic (dibasic) residue sites by prohormone convertases followed by carboxypeptidase E trimming — an architecture that nests multiple YGGFM and YGGFL motifs within the precursor and produces Met- and Leu-enkephalin in a roughly 4:1 ratio, alongside C-terminally extended variants such as Met-enkephalin-Arg-Phe and Met-enkephalin-Arg-Gly-Leu (Goumon and colleagues 1996). Both share the YGGF "message" tetrapeptide — the N-terminal Tyr and Phe⁴ are the recognition elements that engage the opioid receptor binding pocket, with the Gly²–Gly³ spacer providing conformational flexibility (Clynen and colleagues 2014). Both function as agonists at the delta-opioid receptor (OPRD1) and, with weaker affinity, at the mu-opioid receptor, and both are catalogued together with the dynorphins and β-endorphin as the core endogenous opioid neuropeptide family (Clynen and colleagues 2014). Both have been detected across diverse mammalian neuropeptidomes — including in an integrated mass-spectrometric characterisation of the tree shrew (Tupaia belangeri) brain (Petruzziello and colleagues 2012) — confirming their broad conservation in vertebrate nervous systems.

How they differ

The visible difference is one residue: Leu-enkephalin ends in leucine, Met-enkephalin in methionine. The downstream consequences extend through biosynthesis, receptor pharmacology, and evolutionary distribution. Inside the PENK precursor, Met-enkephalin motifs outnumber Leu-enkephalin motifs — mammalian PENK contains seven Met/Leu-enkephalin sequences total, with Met-enkephalin liberated about four times more abundantly than Leu-enkephalin from the same processing pathway (Goumon and colleagues 1996). The two also differ at the receptor pharmacology level when assayed in classical opioid bioassays: on the guinea-pig ileum preparation (mu-receptor-dominant) Leu-enkephalin has an IC50 of approximately 970 nM, while on the mouse vas deferens (delta-receptor-dominant) Leu-enkephalin's IC50 falls to approximately 29 nM — a 33-fold potency ratio favouring the delta-rich tissue (British Journal of Pharmacology 1981). Met-enkephalin in the same paired assays is more potent than Leu-enkephalin on the guinea-pig ileum (the 1981 dermorphin comparison ranks dermorphin as 57× more potent than Met-enkephalin but 294× more potent than Leu-enkephalin on guinea-pig ileum, implying Met-enkephalin is roughly 5× more potent than Leu-enkephalin on that preparation).

Evolutionary distribution is also asymmetric. In the Pacific hagfish (Eptatretus stoutii), a living jawless fish, the proenkephalin-like precursor PENKL1 contains three Met-enkephalin (YGGFM) motifs — two flanked by canonical dibasic cleavage sites — but no canonical Leu-enkephalin (YGGFL) motif at all (Huang and colleagues 2022). Immunoreactive forms of both Met- and Leu-enkephalin have been detected in lamprey and hagfish brain extracts (at 3:1 and 2:1 ratios), though it is noted that the Leu-enkephalin antisera may not distinguish leucine from isoleucine forms (Huang and colleagues 2022). The implication is that the canonical YGGFL Leu-enkephalin sequence appears later in vertebrate evolution than YGGFM, with the mammalian Leu/Met enkephalin pairing emerging after the jawless-fish lineage split (Huang and colleagues 2022).

Modern characterisation work has also diverged. Leu-enkephalin has been used heavily as a chemistry-scale model peptide — for instance, as a short-chain model substrate for evaluating new peptide-synthesis methods and as a scaffold in "libraries-from-libraries" combinatorial chemistry approaches that chemically transform peptide libraries while still attached to solid support (Ostresh and colleagues 1994). Met-enkephalin has been investigated more recently in rodent pharmacology: L-Met-enkephalin and a D-amino-acid enantiomer (d-Met-enkephalin) both showed dose-dependent hepatoprotective effects in acetaminophen-induced liver injury in mice, with the activity abolished by the opioid antagonist naltrexone — directly confirming on-target opioid-receptor mediation (Turčić and colleagues 2025). That pattern of opioid-receptor-dependent protective effects has been demonstrated for L-Met-enkephalin across experimental allergic encephalomyelitis, histamine-induced bronchoconstriction, Arthus skin reaction, delayed skin reaction, adjuvant arthritis, cancer models, and allograft rejection (Turčić and colleagues 2025); the corresponding L-Leu-enkephalin literature is not represented in the dossier sources.

Head-to-head clinical evidence

There are no head-to-head human clinical trials comparing native Leu-enkephalin and Met-enkephalin in the dossier sources — neither peptide is a marketed drug, and both have very short biological half-lives in unmodified form, which has historically limited direct therapeutic application of the native pentapeptides. The most rigorous side-by-side comparison available is preclinical and in vitro: the 1981 dermorphin paper benchmarked dermorphin, morphine, Met-enkephalin, and Leu-enkephalin in matched guinea-pig ileum and mouse vas deferens preparations, generating direct dose-response curves and reporting that naloxone (10 nM) produced similar IC50 shift ratios for Met-enkephalin (3.8), Leu-enkephalin (3.75), morphine (3.38), and dermorphin (4.5) — establishing that all four ligands act through naloxone-sensitive opioid receptors on the same preparations (British Journal of Pharmacology 1981). That paper also reports the IC50 differential between guinea-pig ileum and mouse vas deferens for Leu-enkephalin (970 nM vs 29.2 nM, a ratio of 33), which is the most direct numeric anchor in the dossier for the differential receptor-subtype activity of the two peptides.

Safety profile comparison

Neither native pentapeptide has an FDA label or EMA EPAR with a structured adverse-event profile, and no systematic human safety data for either peptide are captured in the dossier sources. Both are endogenous neuropeptides with very short biological half-lives — they are rapidly cleaved by enkephalin-degrading enzymes, which limits sustained receptor exposure (Ding and colleagues 2020). For both peptides, drug-development effort has shifted toward stabilised analogs incorporating non-proteinogenic amino acids — for example a D-amino acid at position 2 — to slow proteolysis while preserving receptor activity (Ding and colleagues 2020). For Met-enkephalin specifically, the dossier reports that the D-amino-acid enantiomer d-Met-enkephalin retains opioid-receptor-mediated hepatoprotection, with maximal protection in the acetaminophen mouse model at 5 mg/kg and full reversal by naltrexone — evidence that chiral inversion at positions 1, 4, and 5 does not abolish receptor engagement, an effect attributed in part to the achiral glycine residues at positions 2 and 3 (Turčić and colleagues 2025). The equivalent enantiomer data for native Leu-enkephalin is not represented in the dossier sources.

Indication overview

Neither Leu-enkephalin nor Met-enkephalin is approved as a drug in the US or EU. Both are studied as endogenous reference peptides in opioid pharmacology and as chemical scaffolds for opioid analog design; neither has a marketed product, and the dossier reports no registered drug formulation for either native pentapeptide. The proenkephalin-A system overall is reviewed as a potential target for anticonvulsant drug development, with both Met-enkephalin and Leu-enkephalin levels and proenkephalin-A-derived peptides reported as altered in temporal lobe epilepsy and rodent seizure models (Clynen and colleagues 2014). Within preclinical inflammation and immune biology, L-Met-enkephalin is the more extensively characterised of the two peptides, with documented protective activity across multiple opioid-receptor-mediated experimental models (Turčić and colleagues 2025); comparable mechanism-of-action work on native Leu-enkephalin is not present in the dossier sources reviewed here. Within peptide chemistry, by contrast, Leu-enkephalin has served extensively as a short-chain model substrate for methods development and combinatorial-library work (Ostresh and colleagues 1994).